BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//www.barthsyndrome.org//NONSGML kigkonsult.se iCalcreator 2.30.10/
 /
CALSCALE:GREGORIAN
METHOD:PUBLISH
UID:8430e040-f8b3-49c8-8c8a-2128ac63a9c8
X-WR-CALDESC:The Food and Drug Administration (FDA\, the Agency\, or we) is
  announcing a public workshop entitled “Endpoints for Drug Development in 
 Heart Failure.' The purpose of this public meeting is to bring the stakeho
 lder community together to discuss clinical endpoints for trials in heart 
 failure that could be used to support FDA approval of drugs. The workshop 
 will focus on endpoints related to symptoms and physical function. In addi
 tion\, there will be discussion of the need to assess mortality effects of
  drugs under development for heart failure.\n\n
X-WR-RELCALID:648ad99dedd50d6325132c8102a786e3
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
TZNAME:EST
DTSTART:20181104T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
RDATE:20191103T020000
RDATE:20201101T020000
END:STANDARD
BEGIN:DAYLIGHT
TZNAME:EDT
DTSTART:20190310T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
RDATE:20200308T020000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:ee4cf2fc-4c0d-4c32-8013-4f941c924cbd
DTSTAMP:20260429T063945Z
DESCRIPTION:The Food and Drug Administration (FDA\, the Agency\, or we) is 
 announcing a public workshop entitled “Endpoints for Drug Development in H
 eart Failure.' The purpose of this public meeting is to bring the stakehol
 der community together to discuss clinical endpoints for trials in heart f
 ailure that could be used to support FDA approval of drugs. The workshop w
 ill focus on endpoints related to symptoms and physical function. In addit
 ion\, there will be discussion of the need to assess mortality effects of 
 drugs under development for heart failure.\n\n
DTSTART;TZID=America/New_York:20190726T000000
DTEND;TZID=America/New_York:20190726T235900
LOCATION:FDA White Oak Conference Center  10903 New Hampshire Avenue  Build
 ing 31  Silver Spring\, MD 20903
SUMMARY:Public Meeting: Endpoints for Drug Development in Heart Failure
END:VEVENT
END:VCALENDAR